论文部分内容阅读
目的了解成神经细胞瘤雌激素受体（ＥＲ），探索新疗法。方法运用酶联亲和组织化学法检测成神经细胞瘤２９例，选择３例ＥＲ阳性的Ⅳ期患儿，加用三苯氧胺治疗。结果ＥＲ阳性率５１７％（１５／２９）。其中＜１岁组阳性率为２／３（例），１～３岁为２／８（例），４～６岁为３／１０（例），７～１０岁为８／８（例）。病理预后较好类型者ＥＲ阳性率为１６７％（１／６），而预后差类型者为６８４％（１３／１９），显著高于前者（Ｐ＜００５）。３例患儿服用三苯氧胺后疼痛症状暂时缓解或存活期延长。结论成神经细胞瘤ＥＲ阳性率较高，ＥＲ可作为成神经细胞瘤预后的指标。三苯氧胺是潜在的治疗药物。
Objective To understand estrogen receptor (ER) in neuroblastoma and to explore new therapies. Methods Twenty-nine patients with neuroblastoma were detected by enzyme-linked immunosorbent assay (IHC). Three patients with stage Ⅳ ER were selected and treated with tamoxifen. Results The positive rate of ER was 517% (15/29). Among them, the positive rate of 1 year old group was 2/3 (case), 1 to 3 years old was 2/8 (case), 4 to 6 years old was 3/10 (case), 7 to 10 years old was 8/8 (case) . The positive rate of ER was 167% (1/6), while the poor prognosis was 684% (13/19), which was significantly higher than the former (P <005). Three patients with tamoxifen after the temporary relief of pain symptoms or prolonged survival. Conclusion The positive rate of ER in neuroblastoma is high, ER can be used as an index of the prognosis of neuroblastoma. Tamoxifen is a potential therapeutic drug.